期刊
NATURE BIOTECHNOLOGY
卷 30, 期 12, 页码 1244-+出版社
NATURE PORTFOLIO
DOI: 10.1038/nbt.2435
关键词
-
资金
- NYSTEM
- New York Stem Cell Foundation
- Maryland Stem Cell Research Funding
- Commonwealth Foundation for Cancer Research
- Experimental Therapeutics Center at MSKCC
- W.R. Hearst Fund in Experimental Therapeutics
- L.S. Wells Foundation
- National Institutes of Health National Cancer Institute [5 P30 CA008748-44]
- W.H. Goodwin
- A. Goodwin
Patient-specific induced pluripotent stem cells (iPSCs) represent a novel system for modeling human genetic disease and could provide a source of cells for large-scale drug-discovery screens. Here we demonstrate the feasibility of performing a primary screen in neural crest precursors derived from iPSCs that were generated from individuals with familial dysautonomia (FD), a rare, fatal genetic disorder affecting neural crest lineages. We tested 6,912 small-molecule compounds and characterized eight that rescued expression of IKBKAP, the gene responsible for FD. One of the hits, SKF-86466, was found to induce IKBKAP transcription through modulation of intracellular cAMP levels and PKA-dependent CREB phosphorylation. SKF-86466 also rescued IKAP protein expression and the disease-specific loss of autonomic neuronal marker expression. Our data implicate alpha-2 adrenergic receptor activity in regulating IKBKAP expression and demonstrate that small-molecule discovery using an iPSC-based disease model can identify candidate drugs for potential therapeutic intervention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据